Icos halts stroke-drug study after late results disappoint
Seattle Times news services
BOTHELL - Drug developer Icos reported a smaller-than-expected first-quarter loss, but said it was halting study of an experimental stroke treatment after disappointing late-stage trial results.
Icos reported a first-quarter loss of $11.9 million, or 26 cents a share, on revenue of $9.8 million, compared with a loss of $7.2 million, or 17 cents, on revenue of $16.1 million in the same 1999 quarter.
Wall Street analysts had expected the company to report a loss of 43 cents a share for the quarter, according to First Call/Thomson Financial.
Icos said interim results of a Phase 3 study of LeukArrest in patients who have had an ischemic stroke failed to meet predefined criteria for success, and it had halted further study.
Copyright (c) 2000 Seattle Times Company, All Rights Reserved.